CCL

Összesen 10 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038589
035-os BibID:PMID:11590623
Első szerző:Antal-Szalmás Péter (laboratóriumi szakorvos)
Cím:A novel flow cytometric assay to quantify soluble CD14 concentration in human serum / Péter Antal-Szalmás, Ibolya Szöllősi, Gabriella Lakos, Emese Kiss, István Csípő, Andrea Sümegi, Sándor Sipka, Jos A. G. van Strijp, Kok P. M. van Kessel, Gyula Szegedi
Dátum:2001
ISSN:0196-4763
Megjegyzések:BACKGROUND: CD14, the major lipopolysaccharide (LPS)-binding protein of myeloid cells, is found as a soluble molecule in human serum. Recent data describe the presence of elevated soluble CD14 (sCD14) concentration in various disorders, confirming disease activity. A novel, easy, and rapid flow cytometric assay was developed to measure sCD14 levels in serum. METHODS: The assay is based on the competition between membrane-expressed CD14 of isolated monocytes from healthy volunteers and sCD14 in the sample sera for binding to anti-CD14 monoclonal antibodies (mAb; 26ic or 60bca). The amount of cell-associated mAb is determined with a fluorescein isothiocyanate (FITC)-labeled anti-mouse conjugate and flow cytometry. The fluorescence signal is inversely proportional with the amount of serum sCD14. Using dilutions of a standard serum, the concentration of sCD14 in the samples is calculated and compared with results obtained by a commercial sCD14 enzyme-linked immunosorbent assay (ELISA). RESULTS: After optimization, the assay showed log-log linearity of 122.1-984.7 ng/ml sCD14 using mAb 26ic and 29.5-246.2 ng/ml sCD14 using mAb 60bca. It revealed similar results as the ELISA (mAb 26ic: r = 0.88, mAb 60bca: r = 0.92) and provided significantly elevated sCD14 levels in systemic lupus erythematosus patients compared with controls (26ic: 2,213 versus 1,676 ng/ml, P < 0.002; 60bca: 2,625 versus 1,907 ng/ml, P < 0.0002). Receiver operating characteristic curve analysis suggested a reasonable diagnostic efficacy of sCD14 quantification in this autoimmune disease. CONCLUSIONS: The method is easy, rapid, sensitive, and can be used in the follow-up of patients suffering from sepsis or chronic inflammatory disorders.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Cytometry 45 : 2 (2001), p. 115-123. -
További szerzők:Szöllősi Ibolya Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Csípő István (1953-) (vegyész) Sümegi Andrea (1969-) (biológus) Sipka Sándor (1945-) (laboratóriumi szakorvos) Strijp, Jos A. G., van Kessel, Kok P. M., van Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM033375
035-os BibID:WOS:000084138000021
Első szerző:Csípő István (vegyész)
Cím:Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE) / I. Csipő, E. Kiss, P. Soltész, P. Antal-Szalmás, Gy. Szegedi, J. H. M. Cohen, R. P. Taylor, M. Kávai
Dátum:1999
Megjegyzések:The functional activity and the expression of CR1 on the erythrocytes (E) of patients with SLE were, respectively, determined by measuring the binding to E of either complement-opsonized bovine serum albumin (BSA)-anti-BSA immune complexes (ICC) or specific anti-ECR1 MoAbs. We found that both the functional activity and levels of ECR1 in SLE patients homozygous for ECR1 high density allele were significantly lowered compared with healthy controls having the same allele. Soon after plasmapheresis there was a significant increase in E ICC binding activity, and this increased functional activity was stable. Moreover, plasmapheresis reduced the level of immune complexes demonstrable in the circulation of the patients. The expression of ECR1 determined with several different anti-CR1 MoAbs was also elevated as a consequence of plasmapheresis. This elevation was observed for both MoAb 1B4, which competes for the ICC binding site of ECR1, and for MoAb HB8592, which does not, but the time course for the increase in binding of the two MoAbs was different, in that the epitope recognized by MoAb 1B4 increased more rapidly. The present results, considered in the context of previous findings, suggest that more than one mechanism may be operative with respect to the effects of the plasmapheresis in increasing ECR1 levels defined by different epitopes on the molecule.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical and Experimental Immunology 118 : 3 (1999), p. 458-464. -
További szerzők:Kiss Emese (1960-) (belgyógyász, immunológus) Soltész Pál (1961-) (belgyógyász, kardiológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Cohen, J. H. M. Taylor, R. P. Kávai Mária (1930-) (vegyész)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

3.

001-es BibID:BIBFORM040665
035-os BibID:PMID:11550968
Első szerző:Sipka Sándor (laboratóriumi szakorvos)
Cím:Decreased arachidonic acid release in peripheral blood monocytes of patients with systemic lupus erythematosus / Sándor Sipka, Sándor Szántó, Kornélia Szűcs, Ildikó Kovács, Emese Kiss, Péter Antal-Szalmás, Gabriella Lakos, Magdolna Aleksza, Árpád Illés, Pál Gergely, Gyula Szegedi
Dátum:2001
Megjegyzések:OBJECTIVE: To investigate the release of arachidonic acid (AA) in unfractionated peripheral blood mononuclear cells (PBMC), separated monocytes and T lymphocytes of patients with systemic lupus erythematosus (SLE). METHODS: AA release was measured in cells from 56 patients with SLE and from 48 controls. Of the 56 patients with SLE, 38 were receiving glucocorticosteroids and 18 were not. [3H]AA was incorporated into the membranes of PBMC and purified subsets of monocytes and T lymphocytes. The release of [3H]AA was measured both in nonstimulated cells cultured for 24 h and in cell cultures stimulated by phorbol ester (PMA) and Ca2+ ionophore for 4 h. RESULTS: In the PBMC of SLE patients not taking glucocorticosteroids, the release of AA was decreased in both stimulated and nonstimulated cells. There was a decrease of AA production in monocytes but not in T lymphocytes. This phenomenon could be observed in the active and inactive phases of the disease. CONCLUSION: A defect in AA production may exist in the peripheral monocytes of patients with SLE, resulting in decreased release of AA in patients not receiving glucocorticosteroid therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adolescent
Adult
Aged
Arachidonic Acid/analysis/biosynthesis
Biological Markers/blood
Cells, Cultured
Female
Glucocorticoids/administration & dosage
Humans
Lupus Erythematosus, Systemic/blood/drug therapy
Male
Middle Aged
Monocytes/metabolism
Prognosis
Reference Values
Sensitivity and Specificity
Severity of Illness Index
egyetemen (Magyarországon) készült közlemény
Megjelenés:The Journal of Rheumatology. - 28 : 9 (2001), p. 2012-2017. -
További szerzők:Szántó Sándor (1968-) (belgyógyász, reumatológus) Szűcs Kornélia (1945-) (biokémikus) Kovács Ildikó Kiss Emese (1960-) (belgyógyász, immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Aleksza Magdolna Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Gergely Pál (1947-) (biokémikus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM040069
Első szerző:Sipka Sándor (laboratóriumi szakorvos)
Cím:Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus / S. Sipka, K. Szűcs, S. Szántó, I. Kovács, G. Lakos, E. Kiss, P. Antal-Szalmás, G. Szegedi, P. Gergely
Dátum:2001
ISSN:0003-4967
Megjegyzések:OBJECTIVE: To compare the activity of calcineurin in the peripheral blood mononuclear cells (PBMC) of 32 patients with systemic lupus erythematosus (SLE) and 35 healthy controls. METHODS: The activity of calcineurin was assayed in the supernatants of sonicated mononuclear cells. RESULTS: There was no significant difference in the calcineurin activity of patients with SLE not taking glucocorticosteroids (GCS) compared with the healthy controls. On the other hand, the activity of calcineurin was reduced in patients with SLE taking GCS, correlating negatively with the dose of GCS. The stimulation of PBMC by phorbol ester and calcium ionophore decreased the calcineurin activity both in patients with SLE and in healthy controls. GCS could also reduce calcineurin activity in the mononuclear cells of healthy subjects in vitro. CONCLUSIONS: In patients with SLE the decrease in the calcineurin activity of PBMC depended on the dose of GCS used for treatment, and it was not a disease specific alteration. The higher the dose of GCS, the greater the inhibition of calcineurin activity. The reduction of calcineurin activity is a new element in the immunosuppressive effects of GCS during the treatment of patients with SLE.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Adolescent
Adult
Aged
Calcineurin/blood/*drug effects
Case-Control Studies
Cells, Cultured
Dose-Response Relationship, Drug
Female
Glucocorticoids/*therapeutic use
Humans
Ionophores/pharmacology
Leukocytes, Mononuclear/*drug effects/metabolism
Lupus Erythematosus, Systemic/blood/*drug therapy
Male
Methylprednisolone/*therapeutic use
Middle Aged
Tetradecanoylphorbol Acetate/pharmacology
Megjelenés:Annals Of The Rheumatic Diseases 60 : 4 (2001), p. 380-384. -
További szerzők:Szűcs Kornélia (1945-) (biokémikus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kovács Ildikó Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Gergely Pál (1947-) (biokémikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM033370
035-os BibID:WOS:000174053900007 PMID:11908707
Első szerző:Soltész Pál (belgyógyász, kardiológus)
Cím:Plasmapheresis modulates Th1/Th2 imbalance in patients with systemic lupus erythematosus according to measurement of intracytoplasmic cytokines / Pál Soltész, Magdolna Aleksza, Péter Antal-Szalmás, Gabriella Lakos, Gyula Szegedi, Emese Kiss
Dátum:2002
ISSN:0891-6934
Megjegyzések:To examine the possible effect of plasmapheresis on the ratio of Th1/Th2 type cytokine-secreting cells we recruited eight patients with active systemic lupus erythematosus into the present study. They all failed to respond to conventional therapy. A sensitive multiparametric flow cytometric analysis was used for the detection of intracellular IL-4, IL-10 and IFN-gamma. Stimulated peripheral blood cells were analysed by this procedure. Plasmapheresis was performed every second day for three occasions, using a continuous flow type blood cell separator, and a total of 100 ml/body weight kg plasma was removed. Patients received 1 mg/kg/day methylprednisolone during this period. As a result of the procedure, the rate of IFNgamma positive Th cells increased, while the rate of IL-4 and IL-10 expressing CD4 positive cells decreased. Together with these observations the concentration of anti-ds-DNA antibodies decreased after plasmapheresis. A decrease in disease activity index (SLE-DAI) indicated the clinical effectiveness of the therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Autoimmunity. - 35 : 1 (2002), p. 51-56. -
További szerzők:Aleksza Magdolna Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM040671
035-os BibID:PMID:16316784
Első szerző:Sümegi Andrea (biológus)
Cím:Glucocorticosteroid therapy decreases CD14-expression and CD14-mediated LPS-binding and activation of monocytes in patients suffering from systemic lupus erythematosus / Andrea Sümegi, Péter Antal-Szalmás, Magdolna Aleksza, Ildikó Kovács, Sándor Sipka, Margit Zeher, Emese Kiss, Gyula Szegedi
Dátum:2005
ISSN:1521-6616
Megjegyzések:In order to study the possible action of glucocorticosteroids (GCS) on the CD14/Toll like receptor mediated activation of monocytes the CD14-expression, CD14-mediated LPS binding and activation of these cells of patients suffering from Systemic Lupus Erythematosus receiving no, low dose or pulse steroid treatment was studied. The CD14-expression was determined on whole blood monocytes by flow cytometry, while the LPS-binding of an FITC-LPS preparate and the LPS-induced TNFalpha secretion were tested on isolated monocytes. The CD14-dependent and -independent LPS-binding and activation were evaluated with the help of a blocking anti-CD14 mAb. Our results showed that the CD14-expression, CD14-dependent LPS-binding and activation were significantly inhibited by the in vivo applied pulse steroid therapy. In contrast, the CD14-independent LPS-binding and activation were not altered by the GCS treatment. Our data provide further in vivo evidence for a possible new way of GCS therapy is able to initiate its anti-inflammatory action.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
egyetemen (Magyarországon) készült közlemény
Megjelenés:Clinical Immunology 117 : 3 (2005), p. 271-279. -
További szerzők:Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Aleksza Magdolna Kovács Ildikó Sipka Sándor (1945-) (laboratóriumi szakorvos) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szegedi Gyula (1936-2013) (belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM027669
Első szerző:Sümegi Andrea (biológus)
Cím:A CD14, TLR2 és TLR4 gének polimorfizmusainak vizsgálata autoimmun és immunpatomechanizmusú betegségekben / Sümegi Andrea, Dankó Katalin, Kiss Emese, Szegedi Andrea, Tar Tünde, Ponyi Andrea, Szegedi Gyula, Antal-Szalmás Péter
Dátum:2004
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
CD14, TLR2 és TLR4 gének
autoimmun, immunpathomechanizmus
Megjelenés:Magyar Immunológia. - 3 : 3 (2004), p. 69. -
További szerzők:Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Kiss Emese (1960-) (belgyógyász, immunológus) Szegedi Andrea (1964-) (bőrgyógyász) Tar Tünde Ponyi Andrea Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM040289
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Malignancies and soluble tumor antigens in rheumatic diseases / Szekanecz E., András C., Sándor Z., Antal-Szalmás P., Szántó J., Tamási L., Kiss E., Szekanecz Z.
Dátum:2006
ISSN:1568-9972
Megjegyzések:Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Autoimmunity Reviews. - 6 : 1 (2006), p. 42-47. -
További szerzők:András Csilla (1961-) (onkológus szakorvos) Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szántó János (1949-) (onkológus szakorvos) Tamási László Kiss Emese (1960-) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM006180
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus : associations with organ manifestations, immunolaboratory markers and disease activity indices / Éva Szekanecz, Gabriella Szűcs, Zoltán Szekanecz, Tünde Tarr, Péter Antal-Szalmás, Szilvia Szamosi, János Szántó, Emese Kiss
Dátum:2008
Megjegyzések:Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected increased production of CA15-3, CA19-9 and CA125 in rheumatoid arthritis (RA). The production of some TAAs may also be increased in patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and other connective tissue diseases. Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. OBJECTIVES: We assessed levels of TAAs in the sera of SSc, SLE patients, patients with infectious diseases and healthy subjects. Serum TAA levels were correlated with each other, as well as with disease activity markers and organ involvement. METHODS: TAAs including CEA, CA15-3, CA72-4, CA125 and CA19-9 were assessed by immunoassay in the sera of 92 patients with SSc, 40 patients with SLE, 50 age- and sex-matched healthy controls, as well as with 40 patients with current bacterial or viral infections. Normal upper limits for these TAAs were 3.4 mg/l, 25 kU/l, 6.9 kU/l, 35 kU/l and 34 kU/l, respectively. RESULTS: There were significantly more SSc patients showing abnormally high levels of CA19-9 (8.8% vs 2.0%), CA125 (11.0% vs 6.0%) and CA15-3 (28.4% vs 14.0%) in comparison to controls (p < 0.05). In SLE, significantly more patients had elevated levels of CEA (32.5% vs 20.0%), CA19-9 (7.5% vs 2.0%), CA125 (15.0% vs 6.0%) and CA72-4 (15.0% vs 8.0%) than did controls (p < 0.05). The mean absolute serum levels of CEA (6.6+/-1.7 vs 1.8+/-1.4 mg/l) and CA15-3 (22.9 +/- 1.8 vs 18.6 +/- 2.2 kU/l) were also significantly higher in SSc compared to controls (p < 0.05). We found numerous correlations between the serum levels of different TAAs within the SSc and SLE population. Among SSc patients, serum CEA (R = 0.290; p = 0.005), CA15-3 (R = 0.260; p = 0.020) and CA19-9 (R = 0.257; p = 0.013) correlated with renal involvement. Serum CA15-3 also correlated with joint involvement (R = 0.329; p = 0.003), ANA positivity (R = 0.288; p = 0.010) and CRP levels (R = 0.407; p < 0.001). Within the SLE population, serum CA72-4 correlated with central nervous involvement (R = 0.624; p = 0.004) and CA125 correlated with the SLEDAI composite activity index (R = 0.666; p = 0.002). Patients with infections exerted serum TAA patterns similar to healthy controls. CONCLUSION: The concentration of some TAAs may be elevated in the sera of patients with SSc or SLE in comparison to healthy subjects. Pathogenically, most of these TAAs contain carbohydrate motifs and thus they may be involved in inflammation-associated adhesive events. Furthermore, the production of some TAAs may correlate with organ involvement or disease activity in scleroderma or lupus.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Journal of Autoimmunity. - 31 : 4 (2008), p. 372-376. -
További szerzők:Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tarr Tünde (1976-) (belgyógyász, allergológus és klinikai immunológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:

10.

001-es BibID:BIBFORM001945
Első szerző:Szekanecz Éva (onkológus szakorvos)
Cím:Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis : potential adhesion molecules in synovial inflammation? / Szekanecz E., Sándor Z., Antal-Szalmás P., Soós L., Lakos G., Besenyei T., Szentpétery A., Simkovics E., Szántó J., Kiss E., Koch A. E., Szekanecz Z.
Dátum:2007
Megjegyzések:Some tumor-associated antigens (TAAs) are expressed on inflammatory cells. We previously detected carcinoembryonic antigen (CEA; CD66) in the rheumatoid (RA) synovium. The production of CEA, CA19-9, CA125, and CA15.3, may be increased in patients with RA, scleroderma, lupus, and Sjogren's syndrome (SS). Some of these TAAs contain sialylated carbohydrate motifs and they are involved in tumor-associated cell adhesion and metastasis. We assessed levels of TAAs in the sera of RA patients and healthy subjects. Serum TAA levels were correlated with disease markers including serum rheumatoid factor (RF), C-reactive protein (CRP), and anti-CCP antibody levels, DAS28, age disease duration. TAAs including CEA, CA15-3, CA72-4, CA125, and CA19-9, and neuron-specific enolase (NSE) were assessed by immunoassay in the sera of 75 patients with RA and 50 age- and sex-matched healthy controls. Normal upper limits for these TAAs were 3.4 microg/L, 25 kU/L, 6.9 kU/L, 35 kU/L, 34 kU/L, and 16.3 microg/L, respectively. There were significantly more RA patients showing abnormally high levels of CA125 (10.8% versus 7.1%), CA19-9 (8.1% versus 0%), and CA15-3 (17.6% versus 14.3%) in comparison to controls (P < 0.05). The mean absolute serum levels of CA125 (23.9 +/- 1.8 versus 16.8 +/- 2.2 kU/L) and CA19-9 (14.2 +/- 1.2 versus 10.5 +/- 1.6 kU/L) were also significantly higher in RA compared to controls (P < 0.05). Among RA patients, serum CEA showed significant correlation with RF (r = 0.270; P < 0.05). None of the assessed TAAs showed any correlation with CRP, anti-CCP, DAS28, age or disease duration. The concentration of some TAAs may be elevated in the sera of patients with established RA in comparison to healthy subjects. CEA, CA19-9, CA125, and CA15-3 contain carbohydrate motifs and thus they may be involved in synovitis-associated adhesive events. Furthermore, some TAAs, such as CEA, may also correlate with prognostic factors, such as serum RF levels.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatoid arthritis
tumor antigens
anti-CCP antibody
rheumatoid factor
carcinoembryonic antigen
Megjelenés:Annals of the New York Academy of Sciences 1108 (2007), p. 359-371. -
További szerzők:Sándor Zsuzsa (1980-) (pathológus) Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos) Soós Lilla Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Besenyei Tímea (1980-) (reumatológus, belgyógyász) Szentpétery Ágnes (1978-) (reumatológus) Simkovics Enikő Szántó János (1949-) (onkológus szakorvos) Kiss Emese (1960-) (belgyógyász, immunológus) Koch, Alisa E. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:elektronikus változat
DOI
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.